Eugin Group (North American operations)
→
KKR (via IVI-RMA)
Acquisition · Cash · announced Nov 1, 2023
Announced
Nov 1, 2023
Closed
Jan 31, 2024
Economics
Cash()
Pre-deal · pre-deal mark: 2023, year precision · rounding grid ±$100M · IVI-RMA Global press release — Eugin Group acquisition, 2024
Part of KKR/GED Capital €494M (~$534M) acquisition of Eugin from Fresenius; this covers Boston IVF and TRIO
Target
Eugin Group (North American operations)
Fertility · Fertility science
HQ Barcelona, Spain · Founded 1999
Global fertility network including Boston IVF and TRIO (Toronto); 13 labs and 32 satellite offices in North America
- Business Wire - IVI RMA completion announcement (January 31, 2024)
- PitchBook (November 2023) - deal reporting
- Fresenius SE press release (divestiture)
Acquirer
KKR
Healthcare
HQ New York, NY
Global investment firm; major investor in fertility clinic consolidation
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
Added Boston IVF (Harvard-affiliated, 13 labs) and TRIO (Toronto) to IVI-RMA network, consolidating North American fertility market leadership
Evidence ladder
Secondary (press / IR)
Business Wire (January 31, 2024)
Tertiary (trade / analyst)
PitchBook (November 2023)
Limitations
- Citations are press/IR only — two wires of the same announcement are not dual-source. Add a primary filing.
- Part of KKR/GED Capital €494M (~$534M) acquisition of Eugin from Fresenius; this covers Boston IVF and TRIO
- Pre-deal valuation sourced from: IVI-RMA Global press release — Eugin Group acquisition, 2024. Pre-deal market-cap and funding citations do not corroborate the acquisition.
Valuation peers · Fertility
Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer, until you sort.
| Why included | ||||
|---|---|---|---|---|
| Indira IVF | BPEA EQT | Jul 28, 2023 | same evidence class | |
| Hamilton Thorne | Astorg | Jul 22, 2024 | same evidence class | |
| Modern Fertility | Ro | May 19, 2021 | value band |
Same-sector adjacency — not valuation peers
These deals share the sector tag and window but sit outside the 0.25×–4× value band. The dataset keeps them for clinical adjacency, not as price comps.
| Vs this deal | ||||
|---|---|---|---|---|
| IVI-RMA Global | KKR | Mar 1, 2022 |
Other verified deals by KKR
Acquirer program history not already listed as a valuation peer or adjacency row.
No further verified deals
Other verified transactions by KKR are already listed above, or none are in the dataset.
Patient empowerment context
Patient empowerment baseline (HLTH 2022)
No curated mapping — Eugin Group (North American operations) (Fertility). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.
Research workspace (includes heuristic crosswalk) →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v11 · updated 2026-10-19 · 2 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.